BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 34011307)

  • 41. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    Kurian AW; Ward KC; Hamilton AS; Deapen DM; Abrahamse P; Bondarenko I; Li Y; Hawley ST; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2018 Aug; 4(8):1066-1072. PubMed ID: 29801090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
    Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
    Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer.
    Paulo P; Maia S; Pinto C; Pinto P; Monteiro A; Peixoto A; Teixeira MR
    PLoS Genet; 2018 Apr; 14(4):e1007355. PubMed ID: 29659569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ten genes for inherited breast cancer.
    Walsh T; King MC
    Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Retesting of women who are negative for a
    Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
    J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer.
    Gunawardena K; Sirisena ND; Anandagoda G; Neththikumara N; Dissanayake VHW
    BMC Res Notes; 2023 Jun; 16(1):95. PubMed ID: 37277882
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protein-truncating variants in moderate-risk breast cancer susceptibility genes: a meta-analysis of high-risk case-control screening studies.
    Aloraifi F; McCartan D; McDevitt T; Green AJ; Bracken A; Geraghty J
    Cancer Genet; 2015 Sep; 208(9):455-63. PubMed ID: 26250988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
    Fernandes GC; Michelli RA; Galvão HC; Paula AE; Pereira R; Andrade CE; Felicio PS; Souza CP; Mendes DR; Volc S; Berardinelli GN; Grasel RS; Sabato CS; Viana DV; Mauad EC; Scapulatempo-Neto C; Arun B; Reis RM; Palmero EI
    Oncotarget; 2016 Dec; 7(49):80465-80481. PubMed ID: 27741520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families.
    Catucci I; Milgrom R; Kushnir A; Laitman Y; Paluch-Shimon S; Volorio S; Ficarazzi F; Bernard L; Radice P; Friedman E; Peterlongo P
    Fam Cancer; 2012 Sep; 11(3):483-91. PubMed ID: 22692731
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathogenic germline variants in patients with features of hereditary renal cell carcinoma: Evidence for further locus heterogeneity.
    Smith PS; West H; Whitworth J; Castle B; Sansbury FH; Warren AY; Woodward ER; Tischkowitz M; Maher ER
    Genes Chromosomes Cancer; 2021 Jan; 60(1):5-16. PubMed ID: 32830346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
    Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
    Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.